Processa Pharmaceuticals, Inc. (PCSA)
2.02
-0.14
(-6.48%)
USD |
NASDAQ |
Sep 09, 11:40
Processa Pharmaceuticals EPS Diluted (Quarterly) : -1.187 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.187 |
| March 31, 2026 | -1.288 |
| December 31, 2025 | -1.306 |
| September 30, 2025 | -1.808 |
| June 30, 2025 | -6.317 |
| March 31, 2025 | -0.2975 |
| December 31, 2024 | -18.45 |
| September 30, 2024 | -1.033 |
| June 30, 2024 | -1.009 |
| March 31, 2024 | -1.105 |
| December 31, 2023 | -1.87 |
| September 30, 2023 | -1.542 |
| June 30, 2023 | -1.940 |
| March 31, 2023 | -3.533 |
| December 31, 2022 | -16.23 |
| September 30, 2022 | -7.433 |
| June 30, 2022 | -6.480 |
| March 31, 2022 | -4.077 |
| December 31, 2021 | -4.056 |
| September 30, 2021 | -3.847 |
| June 30, 2021 | -4.098 |
| March 31, 2021 | -2.879 |
| December 31, 2020 | -33.89 |
| September 30, 2020 | -10.98 |
| June 30, 2020 | -2.659 |
| Date | Value |
|---|---|
| March 31, 2020 | -3.170 |
| December 31, 2019 | -4.671 |
| September 30, 2019 | -3.116 |
| June 30, 2019 | -3.508 |
| March 31, 2019 | -2.717 |
| December 31, 2018 | -2.205 |
| September 30, 2018 | -3.087 |
| June 30, 2018 | -4.20 |
| March 31, 2018 | -4.20 |
| September 30, 2017 | -549.04 |
| June 30, 2017 | -245.00 |
| March 31, 2017 | -245.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 2.268 |
| Eli Lilly & Co. | 7.939 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -3.266M |
| Total Expenses (Quarterly) | 3.266M |
| Enterprise Value | 5.837M |
| Earnings Yield | -276.7% |
| Normalized Earnings Yield | -270.16 |